Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 6, 2006, Pages 1168-1176

  O'Shaughnessy, Elizabeth M ^a   Meletiadis, Joseph ^a   Stergiopoulou, Theodouli ^a   Demchok, Joanne P ^a   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antagonism; Azoles; Echinocandins; Fractional inhibitory concentration index; Polyenes; Synergy

Indexed keywords

AMPHOTERICIN B; APOTHECON; CASPOFUNGIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; FUNGUS ISOLATION; MICROTITER PLATE ASSAY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS; DRUG ANTAGONISM; DRUG COMBINATIONS; DRUG SYNERGISM; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC; PYRIMIDINES; TRIAZOLES;

EID: 33845367196     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl392     Document Type: Article

References (40)

1. Groll AH, Walsh TJ. Antifungal chemotherapy: Advances and perspectives. Swiss Med Wkly 2002; 132: 303-11.
2. Arikan S, Lozano-Chiu M, Paetznick V et al. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46: 245-7.
3. Manavathu EK, Alangaden GJ, Chandrasekar PH. Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J Antimicrob Chemother 2003; 51: 1423-5.
4. Perea S, Gonzalez G, Fothergill AW et al. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002; 46: 3039-41.
5. Luque JC, Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother 2003; 47: 1452-5.
6. Petraitis V, Petraitiene R, Sarafandi AA et al. Combination therapy in treatment of experimental pulmonary aspergillosis: Synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187: 1834-43.
7. Elanjikal Z, Sorensen J, Schmidt H et al. Combination therapy with caspofungin and liposomal amphotericin B for invasive aspergillosis. Pediatr Infect Dis J 2003; 22: 653-6.
8. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: Review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003; 37 Suppl 3: S188-224.
9. Tascini C, Tagliaferri E, Iapoce R et al. Caspofungin in combination with itraconazole and amphotericin B for the treatment of invasive aspergillosis in humans, with a method to test ex vivo synergism. Clin Microbiol Infect 2003; 9: 901-2.
10. Sims-McCallum RP. Triple antifungal therapy for the treatment of invasive aspergillosis in a neutropenic pediatric patient. Am J Health Syst Pharm 2003; 60: 2352-6.
11. National Commmittee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi: Approved Standard M38-A. NCCLS, Wayne, PA, USA, 2002.
12. Bekersky I, Fielding RM, Dressler DE et al. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 2002; 46: 828-33.
13. Walsh TJ, Karlsson MO, Driscoll T et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48: 2166-72.
14. Walsh TJ, Adamson PC, Seibel NL et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005; 49: 4536-45.
15. Berenbaum MC. A method for testing for synergy with any number of agents. J Infect Dis 1978; 137: 122-30.
16. Eliopoulos G, Moellering RC Jr. Antimicrobial combinations. In: Lorian V, ed. Antibiotics in Laboratory Medicine. Baltimore, MD: The Williams & Wilkins Co., 1996; 330-96.
17. Hidler J. Antimicrobial susceptibility testing. In: Isenberg HD, ed. Clinical Microbiology Procedures Handbook. Washington, DC: ASM Press, 1995; pp. 15.18.11-15.18.20.
18. Meletiadis J, Mouton JW, Meis JF et al. Methodological issues of drug interaction modelling in moulds. Rev Med Microbiol 2003; 47: 106-17.
19. Vitale RG, Afeltra J, Dannaoui E. Antifungal combinations. Methods Mol Med 2005; 118: 143-52.
20. Meletiadis J, Verweij PE, te Dorsthorst DTA et al. Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Med Mycol 2005; 34: 133-52.
21. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
22. Johnson MD, MacDougall C, Ostrosky-Zeichner L et al. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48: 693-715.
23. Berenbaum MC. What is synergy? Pharmacol Rev 1989; 41: 93-141.
24. Yoon J, Urban C, Terzian C et al. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2004; 48: 753-7.
25. Odds FC. Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob Agents Chemother 1982; 22: 763-70.
26. Yu VL, Zuravleff JJ, Bornholm J et al. In-vitro synergy testing of triple antibiotic combinations against Staphylococcus epidermidis isolates from patients with endocarditis. J Antimicrob Chemother 1984; 14: 359-66.
27. Dannaoui E, Lortholary O, Dromer F. In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother 2004; 48: 970-8.
28. Kirkpatrick WR, Perea S, Coco BJ et al. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46: 2564-8.
29. Cuenca-Estrella M, Gomez-Lopez A, Garcia-Effron G et al. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Chemother 2005; 49: 1232-5.
30. Clemons KV, Espiritu M, Parmar R et al. Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005; 49: 4867-75.
31. Sionov E, Mendlovic S, Segal E. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. J Infect 2006; 53: 131-9.
32. Meletiadis J, Petraitis V, Petraitiene R et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: In vitro and in vivo correlation. J Infect Dis 2006; 194: 1008-18.
33. Meletiadis J, te Dortshorst DTA, Verweij PE. The concentration-dependent nature of amphotericin B-itraconazole interaction in vitro against Aspergillus fumigatus: Isobolographic and response surface analysis of complex pharmacodynamic interactions. Int J Antimicrob Agents 2006; 28: 439-449.
34. Lamb D, Kelly D, Kelly S. Molecular aspects of azole antifungal action and resistance. Drug Resist Updat 1999; 2: 390-402.
35. Schaffner A, Bohler A. Amphotericin B refractory aspergillosis after itraconazole: Evidence for significant antagonism. Mycoses 1993; 36: 421-4.
36. Scheven M, Schwegler F. Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro. Antimicrob Agents Chemother 1995; 39: 1779-83.
37. Sugar AM, Liu XP. Interactions of itraconazole with amphotericin B in the treatment of murine invasive candidiasis. J Infect Dis 1998; 177: 1660-3.
38. Moore CB, Sayers N, Mosquera J et al. Antifungal drug resistance in Aspergillus. J Infect 2000; 41: 203-20.
39. Manavathu EK, Vazquez JA, Chandrasekar PH. Reduced susceptibility in laboratory-selected mutants of Aspergillus fumigatus to itraconazole due to decreased intracellular accumulation of the antifungal agent. Int J Antimicrob Agents 1999; 12: 213-19.
40. Cohen BE. Concentration- and time-dependence of amphotericin-B induced permeability changes across ergosterol-containing liposomes. Biochim Biophys Acta 1986; 857: 117-22.